Form 4 for DLB Dolby Laboratories, Inc.
Accepted 2025-02-06 00:00:00 ET · period of report 2025-02-04 · accession 0000950170-25-015637 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-06 | 2025-02-04 | DLB | TEVANIAN AVADIS | Dir | A - Grant | $0.00 | +3,140 | 3,140 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-02-04 | A | A | 3,140 | $0.00 | 3,140 | D | — | — | (F1) Award represents a total of 3,140 restricted stock units granted under the terms of the Issuer's 2020 Stock Plan. Each unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon vesting, which will occur on the earlier of (i) the first anniversary of the date of grant or (ii) the date immediately preceding the date of Issuer's 2026 annual meeting of stockholders, provided that, in either case, the Reporting Person continues to serve as a member of the Issuer's board of directors on such date. (F2) Shares held following the reported transactions include 3,140 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. |